What is Vantis Vascular?
Founded by a team of physicians, Vantis Vascular operates at the intersection of clinical expertise and advanced engineering. The company is primarily focused on the development of high-performance technologies designed to address the complexities of calcified arteries. By prioritizing safety, procedural efficiency, and clinical effectiveness, Vantis Vascular is positioning itself as a critical player in the medical device market. Their proprietary solutions aim to solve long-standing challenges in vascular surgery, providing practitioners with the tools necessary to improve patient outcomes in high-risk, complex procedures.
The company's market position is bolstered by its physician-led foundation, which ensures that product development remains deeply aligned with real-world clinical needs. As the demand for minimally invasive vascular solutions continues to rise, Vantis Vascular's commitment to precision engineering provides a distinct competitive advantage in a crowded healthcare landscape.
How much funding has Vantis Vascular raised?
Vantis Vascular has raised a total of $33.6M across 3 funding rounds:
Other Financing Round
$5M
Series B
$10M
Stock/Share Issuance
$18.6M
Other Financing Round (2024): $5M, investors not publicly disclosed
Series B (2024): $10M, investors not publicly disclosed
Stock/Share Issuance (2026): $18.6M, investors not publicly disclosed
Key Investors in Vantis Vascular
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vantis Vascular?
With the successful closure of this latest financing round, Vantis Vascular is well-positioned to accelerate its research and development initiatives and scale its commercial operations. The infusion of capital will likely be directed toward expanding clinical trials, refining its existing product pipeline, and strengthening its market presence in the United States and beyond. As the company transitions into this next phase of growth, the focus will shift toward regulatory milestones and the broader adoption of its vascular intervention technologies. Investors and industry observers will be closely monitoring how the firm leverages this liquidity to navigate the complexities of the medical device regulatory environment and capture a larger share of the vascular intervention market.
See full Vantis Vascular company page
